$TEVA

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.

Original reporting
Published Jul 29, 2026, 6:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 29, 2026, 6:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wed: Teva jumps but TASE continues to lose ground — source image
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

Teva’s raised revenue guidance is the only explicitly described company-specific fundamental driver, making it the primary tradable signal. Other large movers are reported without disclosed catalysts, reducing conviction.

02

Market read

For traders, the actionable edge is Teva’s guidance-driven repricing amid a broadly weaker TASE tape.

03

What to watch

The article does not provide the magnitude or specifics of Teva’s raised guidance, nor does it explain the catalysts for other movers, so follow-through risk is elevated.

Relevance 7/10Novelty 6/10Timing: same-day reaction after Teva’s Q2 results and raised revenue guidance

Background

The piece is a Tel Aviv market wrap with index declines, sector weakness, and a standout Teva earnings and guidance catalyst.

Company-level read

Ticker impact

$TEVABullishMedium confidence
Context

Teva led the Tel Aviv 35 Index, up 10.17%, after reporting Q2 results and raising revenue guidance.

Expected impact

Bullish bias for the next few sessions as traders digest the raised revenue guidance; watch for follow-through vs mean reversion.

Evidence & confidence

The article attributes the 10.17% jump directly to Q2 results and raised revenue guidance, which is a concrete catalyst for repricing.

$NICEBullishLow confidence
Context

Nice rose 5.79% on the day, contributing to the Tel Aviv 35 Index’s strongest movers alongside Teva.

Expected impact

Short-term positive drift is possible, but conviction is limited without a disclosed fundamental driver.

Evidence & confidence

No earnings, guidance, deal, or other primary event is described for Nice in the text.

$ENLTBearishLow confidence
Context

Enlight Renewable Energy fell 4.79%, the biggest decliner on the Tel Aviv 35 Index, during a broadly weaker market.

Expected impact

Near-term downside pressure could persist if selling is momentum-driven, but fundamentals are unclear from this text.

Evidence & confidence

The body lists the percentage move without any specific news catalyst for ENLT.

$ESLTBearishLow confidence
Context

Elbit Systems fell 4.30% on the day, among the notable decliners on the Tel Aviv 35 Index.

Expected impact

Potential for continued volatility, but directional conviction is low without a catalyst.

Evidence & confidence

The text only states the percentage move and does not mention earnings, guidance, contracts, or other events for Elbit.

$NVMIBearishLow confidence
Context

Nova Ltd. dropped 3.91% on the day, listed as one of the notable losers on the Tel Aviv 35 Index.

Expected impact

Watch for follow-through only if broader risk-off persists; company-specific signal is weak.

Evidence & confidence

No discrete NVMI-specific catalyst is provided beyond the decline.

Market effects

Technology index down 2% and banking down 1.5% suggest risk-off pressure, which can amplify dispersion around idiosyncratic earnings/guidance winners like Teva.

Tel Aviv indices broadly lower, implying traders may be reallocating within Israel equities rather than adding net risk.

Limited direct global linkage in the text; the main global read-through is Teva’s guidance affecting sentiment toward pharma earnings season.

Counterpoint

Teva’s +10% move may partially reflect positioning and could mean higher near-term volatility rather than a durable trend if the guidance details are already anticipated.

Key entities

  • Teva Pharmaceutical Industries Ltd.

    Reported Q2 results and raised revenue guidance, driving a +10.17% jump and highest turnover on the Tel Aviv 35 Index.

  • Nice

    Reported as up 5.79% on the day, but no specific catalyst is described in the text.

  • Enlight Renewable Energy

    Reported as down 4.79%, with no catalyst provided in the text.

Related articles

$TEVAMedAI 8/10

Teva (TEVA) Q2 2026 Earnings Call Transcript

Teva (TEVA) reported Q2 2026 revenue of $4.1B, down 1% year over year due to lower U.S. generic sales. Innovative brands rose, including AUSTEDO $696M (+40%), AJOVY $244M (+56%), and UZEDY $77M (+43%). Non-GAAP EPS was $0.02 and free cash flow was $622M (+31%). 2026 revenue guidance was raised to $16.5B-$16.85B; net debt was $12.9B (2.8x).

$ENLTHighAI 9/10

Enlight jumps on strong Q2 results, higher guidance

Enlight Renewable Energy (ENLT) shares rose after it reported Q2 net profit of $31M, up from $6M a year earlier, and revenue up 55% to $210M. The company cited faster US solar project development and US tax benefits. It raised 2026 revenue guidance to $790M-$820M and reported a 15-year electricity supply deal with Google plus progress on the CO-BAR Arizona project.

$TEVAMed

Why Teva Pharmaceutical Stock Surged This Week

Teva Pharmaceutical (NYSE: TEVA) shares rose about 12.3% over the week, outperforming the S&P 500 and Nasdaq. After its Q2 report on July 29, Teva posted adjusted EPS of $0.02 vs $0.11 expected, but sales of $4.1 billion beat estimates by about $70 million. Full-year guidance: adjusted EPS $1.91-$2.11 and sales $16.5-$16.85B. Teva also plans a direct NYSE listing, replacing ADRs, starting Sept. 14.